ViiV says its HIV PrEP therapy outperformed Gilead's lenacapavir in early-stage trial
Source: SeekingAlpha
2025-10-15 07:49:59 ET
More on Pfizer, GSK, etc.
- GSK: Compelling Value, No Red Flags Ahead Of Earnings, Blenrep FDA Decision Soon
- Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)
- GSK's Hidden Growth Engines Beyond HIV And Oncology
- Pfizer CEO touts China's 'dramatic speed' in biopharma, calls for U.S. collaboration
- Pfizer continued losses for seven consecutive sessions
Read the full article on Seeking Alpha
For further details see:
ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial
Gilead Sciences Inc.
NASDAQ: GILD
GILD Trading
1.13% G/L:
$145.57 Last:
1,642,004 Volume:
$143.50 Open:
GILD Latest News
March 03, 2026 09:00:00 am
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
March 02, 2026 08:30:00 am
Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia
February 25, 2026 01:44:00 pm
Gilead's Single-Tablet Regimen of Bictegravir and Lenacapavir Maintained Virological Suppression in People With HIV Who Switched Antiretroviral Therapy
February 24, 2026 10:58:00 am
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
GILD Stock Data
$185,419,569,657
1,228,272,827
0.07%
1237
N/A
Pharmaceuticals
Healthcare
US
Foster City
